MedPath

Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Clinical Trials
Related News

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Phase 2
Recruiting
Conditions
Carcinoma, Neuroendocrine
Tumor, Neuroendocrine
Tumors, Neuroendocrine
Neuroendocrine; Carcinoma
Small Cell; Receptors
Interventions
First Posted Date
2024-05-09
Last Posted Date
2025-05-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT06406465
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Phase 2
Recruiting
Conditions
Oligometastatic Prostate Cancer
Locally Advanced Prostate Cancer
Interventions
First Posted Date
2024-04-26
Last Posted Date
2024-04-26
Lead Sponsor
The First Affiliated Hospital of Xiamen University
Target Recruit Count
40
Registration Number
NCT06387056
Locations
🇨🇳

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Phase 3
Not yet recruiting
Conditions
Local Advanced or Metastatic NSCLC
Interventions
Drug: JMT101 Injection
First Posted Date
2024-04-23
Last Posted Date
2024-04-23
Lead Sponsor
Shanghai JMT-Bio Inc.
Target Recruit Count
398
Registration Number
NCT06380348

Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy

Phase 2
Recruiting
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Radiation: radioembolization with Y-90
First Posted Date
2024-04-19
Last Posted Date
2024-05-24
Lead Sponsor
Francesco De Cobelli
Target Recruit Count
33
Registration Number
NCT06375915
Locations
🇮🇹

Department of Radiology, IRCCS Ospedale San Raffaele, Milano, Italy

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

Phase 2
Not yet recruiting
Conditions
Limited-stage Small-cell Lung Cancer
Interventions
First Posted Date
2024-04-19
Last Posted Date
2024-04-19
Lead Sponsor
Beijing Chest Hospital, Capital Medical University
Target Recruit Count
60
Registration Number
NCT06375109

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Phase 1
Recruiting
Conditions
Neuroendocrine Carcinoma
Interventions
Biological: ZG005
Drug: Placebo
First Posted Date
2024-04-18
Last Posted Date
2024-06-14
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
93
Registration Number
NCT06372626
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, Beijing, China

The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy

Completed
Conditions
Bladder Cancer Stage II
Bladder Cancer
Bladder Cancer Stage I
Interventions
First Posted Date
2024-04-10
Last Posted Date
2024-04-10
Lead Sponsor
Ankara Etlik City Hospital
Target Recruit Count
221
Registration Number
NCT06358599
Locations
🇹🇷

Ankara Etlik City Hospital, Ankara, Turkey

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2024-03-29
Last Posted Date
2024-07-18
Lead Sponsor
Hansoh BioMedical R&D Company
Target Recruit Count
1048
Registration Number
NCT06336707
Locations
🇨🇳

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Shanghai, Shanghai, China

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Phase 3
Not yet recruiting
Conditions
Cervical Cancer
Interventions
Biological: Nimotuzumab
Radiation: External Beam Radiotherapy (EBRT)
Radiation: Brachytherapy
First Posted Date
2024-03-27
Last Posted Date
2024-03-27
Lead Sponsor
Biotech Pharmaceutical Co., Ltd.
Target Recruit Count
460
Registration Number
NCT06333821

Hypofractionated Radiochemotherapy

Phase 2
Not yet recruiting
Conditions
Uterine Cervix Cancer
Interventions
Radiation: intensity modulated radiation therapy (IMRT)
Radiation: high-dose-rate (HDR) brachytherapy
First Posted Date
2024-03-26
Last Posted Date
2025-03-06
Lead Sponsor
Denise Fabian
Target Recruit Count
20
Registration Number
NCT06331468
Locations
🇺🇸

Markey Cancer Center, Lexington, Kentucky, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy